Orforglipron and Heart Events in People With Heart Artery Disease or Chronic Kidney Disease
Tests orforglipron against placebo for heart problems in adults with artery or kidney disease.
Plain-language title generated from the registry record
Registry title: A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
Key facts
- Where
- Ahmedabad, Bangalore, Belagavi, Bhubaneswar, Guntur, Hubli, Hyderabad, Kanpur, Kolkata, Kozhikode, Lucknow, Nagpur, New Delhi, Patna, Raipur, and Vadodara, IndiaSee the 20 sites
- Phase
- Phase 3
Where in India
- Gujarat Endocrin Pvt LtdAhmedabad, IndiaTaking people
- Life Care Hospital and Research CentreBangalore, IndiaTaking people
- Belagavi Institute of Medical Sciences - BelagaviBelagavi, IndiaTaking people
- KLES Dr. Prabhakar Kore Hospital & M.R.CBelagavi, IndiaTaking people
- All India Institute of Medical SciencesBhubaneswar, IndiaTaking people
- Endolife Speciality HospitalsGuntur, IndiaTaking people
- Karnataka Medical College and Research Institute, HubballiHubli, IndiaTaking people
- Osmania General HospitalHyderabad, IndiaTaking people
- K care HospitalKanpur, IndiaTaking people
- Nil Ratan Sircar Medical College and HospitalKolkata, IndiaTaking people
- Government Medical College, KozhikodeKozhikode, IndiaTaking people
- King George's Medical UniversityLucknow, IndiaTaking people
- All India Institute of Medical Sciences (AIIMS) - NagpurNagpur, IndiaTaking people
- Central India Cardiology and Research InstituteNagpur, IndiaTaking people
- Lata Mangeshkar Hospital - DigdohNagpur, IndiaTaking people
- G.B. Pant Institute of Postgraduate Medical Education & ResearchNew Delhi, IndiaTaking people
- National Heart Institute DelhiNew Delhi, IndiaTaking people
- All India Institute of Medical Sciences - Patna - Aurangabad RoadPatna, IndiaNot yet recruiting
- SMC Heart Institute and IVF Research CentreRaipur, IndiaTaking people
- Rhythm Heart Institute - A Unit of SLPLVadodara, IndiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07241390EU 2025-523123-22-00
- Record updated
- 4 November 2026
- Original description
The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.Read full original descriptionShow less
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Orforglipron on the Incidence of Major Adverse Cardiovascular Events in Participants With Established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease
The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.
Inclusion: Have established ASCVD and/or CKD.
Exclusion: Have had a major heart condition within 60 days prior to screening; Have type 1 diabetes; Have New York Heart Association Functional Classification Class IV heart failure.